Abstract
Vista Sohrab, Matthew J. Christmas, Gustaf Brander, Eric Pederson, Raphaela Pensch, Brittney Kenney, 宋诚诚, Ola Wallerman, Elisabeth Sundström, Asa Karlsson, Linnea L Monsen, PGC TS/OCD working group, Kathryn A. Lord, Nora I. Strom, Christian Rück, Manuel Mattheisen, James J Crowley, Jennifer R. S. Meadows, Elinor K Karlsson, Kerstin Lindblad‐Toh
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
europepmc
Confidence 96%
unpaywall
Confidence 95%
openalex
Confidence 95%
datacite
Confidence 0%
No local citing links have been materialized yet.
Genome-wide analyses identify 30 loci associated with obsessive-compulsive disorder
10.1038/s41588-025-02189-z · 2025
10.1016/s0278-5846(00)00104-4
10.1016/s0278-5846(00)00104-4
10.1126/science.1222794
10.1126/science.1222794
10.1176/appi.ajp.20250944
10.1176/appi.ajp.20250944
10.4088/jcp.19r13085
10.4088/jcp.19r13085
Unresolved referenced work
Kept as external metadata until matched
10.1016/j.pnpbp.2005.11.028
10.1016/j.pnpbp.2005.11.028
10.1136/bmjopen-2024-090431
10.1136/bmjopen-2024-090431
10.1176/appi.ajp.2020.20111601
10.1176/appi.ajp.2020.20111601
10.1007/s11920-026-01705-0
10.1007/s11920-026-01705-0
10.1038/s41467-023-38695-z
10.1038/s41467-023-38695-z
10.1016/j.pharmthera.2011.09.006
10.1016/j.pharmthera.2011.09.006
10.1016/j.conb.2014.08.008
10.1016/j.conb.2014.08.008
Glutamatergic medications for obsessive-compulsive and related disorders: A systematic review and meta-analysis: A systematic review and meta-analysis. JAMA Netw
2025
10.1176/appi.ajp.2017.17030283
10.1176/appi.ajp.2017.17030283
10.1038/s41586-022-04434-5
10.1038/s41586-022-04434-5
10.1371/journal.pgen.1008489
10.1371/journal.pgen.1008489
10.1001/jama.2017.2200
10.1001/jama.2017.2200
10.1038/s41588-022-01174-0
10.1038/s41588-022-01174-0
10.1126/science.abn3943
10.1126/science.abn3943
10.1016/j.cell.2015.01.006
10.1016/j.cell.2015.01.006
10.1016/j.mcpro.2022.100261
10.1016/j.mcpro.2022.100261
10.1038/s41596-022-00797-1
10.1038/s41596-022-00797-1
10.1016/j.celrep.2025.116044
10.1016/j.celrep.2025.116044
Comparative neurogenetics of dog behavior complements efforts towards human neuropsychiatric genetics
10.1007/s00439-023-02580-y · 2023
10.2460/javma.2002.221.1445
10.2460/javma.2002.221.1445
10.1176/appi.books.9780890425596
10.1176/appi.books.9780890425596
Efficacy of fluoxetine for canine behavioral disorders
10.1016/j.jveb.2019.05.006 · 2019
Randomized, controlled clinical trial of the efficacy of fluoxetine for treatment of compulsive disorders in dogs
10.2460/javma.235.6.705 · 2009
Phenomenology of early childhood onset obsessive compulsive disorder
10.1007/s10862-008-9094-0 · 2009
10.1016/j.pnpbp.2013.04.002
10.1016/j.pnpbp.2013.04.002
10.1038/mp.2009.111
10.1038/mp.2009.111
10.1186/gb-2014-15-3-r25
10.1186/gb-2014-15-3-r25
10.1038/s41467-017-00831-x
10.1038/s41467-017-00831-x
10.1038/ejhg.2012.245
10.1038/ejhg.2012.245
10.1038/ng.2007.10
10.1038/ng.2007.10
10.1038/nature04338
10.1038/nature04338
10.1126/science.abk0639
10.1126/science.abk0639
Genetic testing predicts appearance but not behavior in dogs
10.1073/pnas.2421752122 · 2025
Unresolved referenced work
Kept as external metadata until matched
10.1038/s41588-018-0059-2
10.1038/s41588-018-0059-2 · doi-reference
10.5281/zenodo.20137136
10.5281/zenodo.20137136 · doi-reference
valr: Reproducible genome interval analysis in R
10.12688/f1000research.11997.1 · doi-reference
10.1093/bioinformatics/btq033
10.1093/bioinformatics/btq033 · doi-reference
10.1093/nar/gkj144
10.1093/nar/gkj144 · doi-reference
10.5281/zenodo.20136916
10.5281/zenodo.20136916 · doi-reference
10.1101/gr.177881.114
10.1101/gr.177881.114 · doi-reference
10.1371/journal.pgen.1010299
10.1371/journal.pgen.1010299 · doi-reference
10.1093/bib/bbs017
10.1093/bib/bbs017 · doi-reference
10.21105/joss.00731
10.21105/joss.00731 · doi-reference
10.32614/cran.package.grab
10.32614/cran.package.grab · doi-reference
10.1038/ng.608
10.1038/ng.608 · doi-reference
10.1093/bioinformatics/btq559
10.1093/bioinformatics/btq559 · doi-reference
10.1016/j.ajhg.2018.07.015
10.1016/j.ajhg.2018.07.015 · doi-reference
10.1093/gigascience/giab008
10.1093/gigascience/giab008 · doi-reference
10.1038/s41588-020-00756-0
10.1038/s41588-020-00756-0 · doi-reference
10.1186/s13742-015-0047-8
10.1186/s13742-015-0047-8 · doi-reference
10.1093/bioinformatics/btp352
10.1093/bioinformatics/btp352 · doi-reference
10.1038/ng.806
10.1038/ng.806 · doi-reference
10.1007/bf02289447
10.1007/bf02289447 · doi-reference
10.1207/s15327906mbr0102_10
10.1207/s15327906mbr0102_10 · doi-reference
10.1007/bf02291817
10.1007/bf02291817 · doi-reference
10.1111/j.2044-8317.1950.tb00285.x
10.1111/j.2044-8317.1950.tb00285.x · doi-reference
An evolutionary perspective on dog behavioral genetics
10.1146/annurev-animal-111523-101954 · doi-reference
10.1073/pnas.1814292116
10.1073/pnas.1814292116 · doi-reference
10.1038/s41588-020-00735-5
10.1038/s41588-020-00735-5 · doi-reference
10.1016/j.neubiorev.2025.106320
10.1016/j.neubiorev.2025.106320 · doi-reference
10.1523/jneurosci.1869-10.2010
10.1523/jneurosci.1869-10.2010 · doi-reference
Randomized controlled trial of the effects of high-dose ondansetron on clinical symptoms and brain connectivity in obsessive-compulsive and tic disorders
10.1176/appi.ajp.20240294 · doi-reference
10.1038/s41598-023-47931-x
10.1038/s41598-023-47931-x · doi-reference
10.1007/s00335-025-10178-0
10.1007/s00335-025-10178-0 · doi-reference
10.1038/npp.2013.150
10.1038/npp.2013.150 · doi-reference
Pharmacological augmentation of serotonin reuptake inhibitors in patients with obsessive-compulsive disorder: A network meta-analysis
10.1111/acps.13568 · doi-reference
N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial
10.1016/j.pnpbp.2022.110550 · doi-reference
10.1038/s41586-025-09214-w
10.1038/s41586-025-09214-w · doi-reference
10.1126/science.1234733
10.1126/science.1234733 · doi-reference
10.1016/s0896-6273(01)00564-5
10.1016/s0896-6273(01)00564-5 · doi-reference
10.1038/s41598-017-15028-x
10.1038/s41598-017-15028-x · doi-reference
10.3389/fmolb.2022.1019636
10.3389/fmolb.2022.1019636 · doi-reference
10.1038/s41573-021-00371-6
10.1038/s41573-021-00371-6 · doi-reference